Axsome Therapeutics, Inc. (AXSM)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Axsome Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Axsome Therapeutics, Inc. (AXSM) has returned -7.46% so far this year and 44.92% over the past 12 months. Looking at the last ten years, AXSM has achieved an annualized return of 34.16%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Nov 19, 2015, AXSM's average daily return is +0.26%, while the average monthly return is +5.64%. At this rate, your investment would double in approximately 1.1 years.

Historically, 51% of months were positive and 49% were negative. The best month was Jan 2019 with a return of +197.5%, while the worst month was Jan 2018 at -50.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, AXSM closed higher 48% of trading days. The best single day was Jan 7, 2019 with a return of +161.2%, while the worst single day was Aug 9, 2021 at -46.5%.

Axsome Therapeutics, Inc. has an annualized alpha of 68.79%, beta of 0.97, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since November 20, 2015.

• This stock captured 180.24% of S&P 500 Index gains but only 89.02% of its losses — a favorable profile for investors.
• R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AXSM ranks 76 for risk / return — better than 76% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Axsome Therapeutics, Inc. (AXSM) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Axsome Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Axsome Therapeutics, Inc. was 86.65%, occurring on Dec 27, 2018. Recovery took 59 trading sessions.

The current Axsome Therapeutics, Inc. drawdown is 10.62%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Axsome Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Axsome Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.